Physician profile
Landon Kozai
NPI 1912575903
$1,339.91
in general payments reported to CMS, 2019-2025
14 companies · $960 in 2025
The $960 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $76.24 · 2024: $304 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,256 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.91 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $468.46 | 2024-2025 | |
| Janssen Biotech, INC. | $219.79 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $107.50 | 2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $107.12 | 2024-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $78.33 | 2025 | Voquezna |
| Madrigal Pharmaceuticals | $69.05 | 2025 | Rezdiffra |
| Celltrion USA INC. | $56.40 | 2025 | Vegzelma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.84 | 2025 | Xifaxan |
| Lantheus Medical Imaging, INC. | $53.40 | 2023 | Definity |
| Genzyme Corporation | $30.85 | 2025 | |
| Intercept Pharmaceuticals, INC. | $27.44 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $25.38 | 2024 | Eliquis |
| Lundbeck LLC | $22.84 | 2023 | Vyepti |
| Lilly USA, LLC | $18.51 | 2025 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Landon Kozai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.